

5 December 2012

AquaBounty Technologies, Inc.
(“AquaBounty” or “the Company”)

Update on Proposed Offer and Financing

Further to the announcements of 31 October and 16 November 2012, AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, comments on the proposed tender offer (“the Offer”) by Intrexon Corporation (“Intrexon”), a privately held biotechnology company, and announces bridging finance.

Proposed Offer

AquaBounty has been informed that Intrexon has issued the Offer, a copy of which has been posted to the Company’s website, to all other shareholders to purchase the issued and outstanding share capital of the Company not owned by Intrexon, which represents 52.44% of the Company. Shareholders should expect to receive a circular from Intrexon to tender their shares for a price of \$0.123 per share.

Background to the Offer

On 16 November, Intrexon completed the purchase of 48,631,444 common shares (47.56 % of the current issued share capital of the Company) from Linnaeus Capital Partners, B.V. (“Linnaeus”) and its subsidiary Tethys Ocean, B.V. (“Tethys”).

As stated in the announcement of 31 October, AquaBounty’s Certificate of Incorporation requires any person that acquires securities representing 30% or more of its voting power to make a cash offer for the remaining issued and outstanding capital stock of the Company at the highest price that person has paid in the preceding 12 months.

Therefore, Intrexon has informed the Board that it will make an offer to all other shareholders at the same price per share as that paid to Linnaeus and Tethys, for the issued and outstanding share capital of the Company not owned by them.

Directors’ Recommendation

The Directors of AquaBounty have reviewed the Offer and, taking into account the Company’s current situation and future outlook, the Board has determined that it is not able to make a recommendation on whether or not shareholders should tender their shares. However, Richard Clothier, Chairman, and Richard Huber, non executive director, with a combined shareholding of 1,365,663 shares constituting 1.34% of the outstanding issued share capital, have confirmed to the Board that they do not intend to sell their shares to Intrexon, as they believe that the Company’s future interests are best served by continuing to be a publicly traded company. No other Directors hold shares.

Additionally, the Directors continue to believe that, were FDA approval to be received, the market potential for AquAdvantage[®] Salmon and other AquaBounty products could be substantial. However, shareholders should also note that the Company has not received further information on the status of its FDA application subsequent to the update provided in the Company’s interim results announcement of 25 September 2012 and there are no guarantees that the Company will receive FDA approval in the future or, in the event that it does, that there would be consumer acceptance of the Company’s AquAdvantage[®] fish products.

Financing

AquaBounty has agreed to a short-term bridge loan financing of \$500,000 by Intrexon to cover the Company's working capital requirements until an equity fundraising can be completed. The terms of the loan include an interest rate of 3%, a maturity of 180 days, and repayment through the proceeds of a capital raising transaction.

Following the receipt of the loan, the Company will have sufficient capital, combined with tight cost control, to allow the Company to continue operations until March 2013.

AquaBounty's Chairman, Richard Clothier, commented: "The Directors welcome the Intrexon investment as a sign of confidence in the Company, and expect that their knowledge and experience in relevant technology will add substantial value."

Forward-looking statements

This announcement contains (or may contain) certain forward-looking statements with respect to the Company and certain of its current goals and expectations relating to its future financial condition and performance and which involve a number of risks and uncertainties. The Company cautions readers that no forward-looking statement is a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statements. These forward-looking statements sometimes use words such as "aim", "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", or other words of similar meaning.

Any forward-looking statements made in this announcement by or on behalf of the Company speak only as at the date they are made. Except as required by the Financial Services Authority, the London Stock Exchange plc or applicable law, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this document to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based

Enquiries:

AquaBounty Technologies

David Frank, Chief Financial Officer

+1 978 648 6000

Nomura Code Securities

Giles Balleny

+44 (0)207 776 1200

Luther Pendragon

Harry Chathli, Claire Norbury

+44 (0)207 618 9100